Bibliography
[1] Gorbalenya AE et al. Coronaviridae study group of the international Committee on Taxonomy of Viruses. The species severe acute respiratory syndrome-related coronavirus: classifying 2019- nCoV and naming it SARS-CoV-2. Nat Microbiol. (2020), 5:536–44.
[2]World Health Organization. WHO Director-General’s Remarks at the Media Briefing on 2019-nCoV on 11 February 2020. (2020). Available online at: https://www.who.int/ dg/speeches/detail/who-director-general-s-remarksat-the-media-briefing-on-2019-ncov- on-11-february-2020 (accessed June 22, 2020).
[3] Centers for Disease Control and Prevention (CDC). Coronavirus Disease 2019 (COVID-19). (2020). Available online at: https://www.cdc.gov/coronavirus/2019-ncov/ symptoms-testing/symptoms.html (accessed June 23, 2020).
[4 ]Mao L et al. Neurological manifestations of hospitalized patients with COVID19 in Wuhan, China: a retrospective case series study. BMJ (2020) 77:683–90.
[5] Wang D et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. JAMA. (2020) 323:1061–9.
[6] Antonio C et al. Anesthesiologic management of pregnant women with SARS-COV-2 infection undergoing cesarean delivery. Clin. Exp. Obstet. Gynecol. 2021, 48(3), 628–630.
[7] Coviello A et al. Protocols of Anesthesia Management in Parturients with SARS-CoV-2 Infection. Healthcare (Basel). 2022 Mar 12;10(3):520.
[8] Di Mascio et al. ”Risk factors associated with adverse fetal outcomes in pregnancies affected by Coronavirus disease 2019 (COVID-19): a secondary analysis of the WAPM study on COVID-19” Journal of Perinatal Medicine, vol. 48, no. 9, 2020, pp. 950-958
[9]Organization, W. H. The different types of COVID-19 vaccines. Available at: https://www.who.int/news-room/feature-stories/detail/the-race-for-a- covid-19-vaccine-explained
[10]Lucchese G et al SARS-CoV-2 and Guillain-Barré syndrome: molecular mimicry with human heat shock proteins as potential pathogenic mechanism. Cell Stress Chaperones. 2020 Sep;25731-5.
[11]Jacobs BC et al. The spectrum ofantecedent infections in Guillain- Barré syn-drome: a case-control study. Neurology. 1998;51(4):1110-15.
[12]Fokke C et al. Diagnosis of Guillain-Barré syndrome and validation of Brighton criteria. Brain. 2014 Jan;137(Pt 1):33-43.
[13] Chen RT et al. The vaccine adverse event reporting system (VAERS). Vaccine. 1994, 12:542-550.
[14].Chen Y et al. Vaccines and the risk of Guillain-Barré syndrome. Eur J Epidemiol. 2020 Apr;35(4):363-70.
[15] Huang C et al. Clinical features ofpatients in-fected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497- 506.
[16] Li YC et al. The neuroinvasive potential ofSARS-CoV2 may play a role in the respiratory failure ofCOVID- 19 patients. J Med Virol. 2020;92(6):552- 555.
[17] Sedaghat Z et al. Guillain Barre syndrome associated with COVID- 19 infection: a case report. J Clin Neurosci. 2020;76:233- 235
[18] Filosto M et al. Guillain- Barré syndrome and COVID-19: an observational multicentre study from two Italian hotspot regions. J Neurol Neurosurg Psychiatry. 2021 Jul;92(7):751-756.
[19] Haber P et al. Vaccines and Guillain-Barré syndrome. Drug Safety. 2009, 32:309-323.